1Jin F, Xie Z, Kuo CJ,et al. Cotargeting tumor and tumor endo- thelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combina- tion therapy[ J]. Cancer Gene Ther,2005,12 (3) :257 - 267.
2Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperincal permanent brachytherapy of prostate cancer[ J]. Int J Radiat Oncol Biol Phys, 1999,44 (4) :789 - 799.
3Wilson GD, Hasan Y, Mitchell C, et al. High Dose Rate. Bracht- herapy Boost for Prostate Cancer: Is More BED better[ J] ? Int J Radiat Oncol Biol Phys, 2007,67 ( 3 ) : 316.
7Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer[ J]. J Clin Oncol,2000,18 (23) : 3904 - 3911.
8Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional frac- tionation in patients with high-risk prostate cancer[ J]. Int J Ra- diat Oncol Bios Phys, 2010,78 ( 1 ) : 11 - 18.
